Pricing Log in Create free account

Coherus Oncology, Inc. (CHRS) vs Precision BioSciences, Inc. (DTIL)

Coherus Oncology, Inc. and Precision BioSciences, Inc. are both Biotechnology companies. Coherus Oncology, Inc. and Precision BioSciences, Inc. are of similar size ($170.3M and $165.3M). Coherus Oncology, Inc. grew revenue faster over the last twelve months: 61.0% against −11.9%. Precision BioSciences, Inc. has the higher net margin (0.00% vs −259.4%) and the higher return on invested capital (0.00% vs 0.00%). Across the 18 metrics below, Precision BioSciences, Inc. leads on 11 and Coherus Oncology, Inc. on 7.

Valuation

Metric CHRS DTIL Biotechnology median
P/E n/m n/m 8.50
P/S 3.04 3.31 9.71
P/B 2.54 3.29 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 5.14 1.87 9.21
Earnings yield (103.00%) (48.35%) (33.15%)
Free cash flow yield (120.77%) (35.07%) (25.50%)

Profitability

Metric CHRS DTIL Biotechnology median
Gross margin 68.94% 100.00% 65.16%
Operating margin (311.56%) 0.00% 0.00%
Net margin (259.41%) 0.00% 0.00%
Free cash flow margin (365.22%) 0.00% 0.00%
Return on equity (146.27%) (132.91%) (56.36%)
Return on assets (41.90%) (44.91%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric CHRS DTIL Biotechnology median
Revenue growth (TTM) 61.00% (11.87%) 6.02%
EPS growth (last fiscal year) 472.00% (442.31%) 30.26%
Revenue growth, 5-year CAGR (38.41%) 7.13% 9.41%
Net income growth, 5-year CAGR 4.91% 0.00% 0.00%

Health

Metric CHRS DTIL Biotechnology median
Debt to equity 0.61 0.50 0.00
Current ratio 1.77 12.82 4.72
Net debt to EBITDA 0.76 1.86 0.96

Dividend

Metric CHRS DTIL Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CHRS DTIL Biotechnology median
Market cap 165.32m 170.30m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack